Future directions in the management of pain by intraspinal drug delivery
Future directions in the management of pain by intraspinal drug delivery
复制标题
DOI：
10.1016/s0885-3924(00)00201-3
复制
发表时间：
2000-08-01
影响因子：
4.7
通讯作者：
Hassenbusch, SJ
中科院分区：
文献类型：
--
作者：
Bennett, G;Deer, T;Hassenbusch, SJ
通过椎管内给药治疗疼痛使医生能够靶向特定的作用部位。虽然这种新方法越来越多地使用，但需要精心设计的研究。一个主要的限制是缺乏关于用于鞘内递送的现有药物的公开信息。(The这些信息的优点和缺点在随附的文献综述文章中进行了综述。）有前途的药物，如布比卡因，氢吗啡酮，吗啡/可乐定组合值得进一步研究的大型前瞻性（理想的随机和双盲）临床安全性和有效性研究。这些研究可以为疼痛管理指南提供数据，例如前面的论文中所包括的数据：研究还必须增加，在临床开发和cl，药物批准期间的制剂，化学稳定性/相容性药代动力学和毒理学的pss问题。最后，更多的基础研究和其他潜在药物的早期试验。鞘内疼痛管理（例如，需要加巴喷丁）（C）美国癌症疼痛缓解委员会，2000年。
Management of pain by intraspinal delivery of drugs enables physicians to target specific sites of action. While this novel approach is gaining increasing use, well-designed studies are needed. A major limitation is the lack of published information on existing drugs used for intrathecal delivery. (The strengths and weaknesses of this information are reviewed in the accompanying literature review article.) Promising agents such as bupivacaine, hydromorphone, and morphine/clonidine combinations warrant further research in large prospective (ideally randomized and double-blind) clinical safety and efficacy studies. These studies may provide data for pain management guidelines, such as those included in the preceding paper: Research must also add,pss issues of formulation, chemical stability/conpatibility pharmacokinetics, and toxicology during clinical development and cl,drug approval. Finally, more basic studies and early phase trials of other potential agents. intrathecal pain management (e.g., gabapentin) are needed (C) U.S. Cancer Pain Relief Committee, 2000.